Lutein for Age-related Macular Degeneration

Verdict: Modest benefit for slowing advanced AMD

For people who already have intermediate or advanced age-related macular degeneration, lutein (with zeaxanthin) can modestly slow progression to advanced disease, but it does not prevent AMD in healthy eyes, cannot reverse existing damage, and the evidence remains disputed across regulators.

B 🟡 B Preliminary Evidence Disputed

🔬Why this grade7-layer evidence engine

The grade sits at a cautious "Preliminary" tier because the evidence is unusually strong for a supplement yet genuinely mixed. The large AREDS2 trial (PMID 23644932, n=4,203) found no significant overall benefit (HR 0.90, P=.12); the clearer effect appeared only in the subgroup with the lowest dietary lutein intake (HR 0.74) and when lutein/zeaxanthin replaced beta-carotene (late-AMD HR 0.82, neovascular HR 0.78; PMID 24310343). A 10-year follow-up (PMID 35653117) confirmed this edge over beta-carotene (HR 0.85) without raising lung-cancer risk.

It is rated "disputed" because authorities disagree. A 2017 Cochrane review (PMID 28756618) judged standalone lutein/zeaxanthin to be low-certainty with little effect (RR 0.94, 95% CI 0.87-1.01). Regulators are split: the US FDA accepts lutein only as a safe food ingredient and rejected an AMD health claim, EFSA rejected all vision claims, and the UK NHS instructs prescribers not to start it and to stop existing prescriptions.

Clinical bodies, by contrast, are broadly supportive: Mayo Clinic, Cleveland Clinic, Harvard Health and ophthalmology society guidance endorse the AREDS2 formula for intermediate-to-advanced AMD. The honest reading is a conditional yes for slowing progression in that specific group, especially low-intake individuals, delivered as part of a multi-component formula rather than lutein alone, with no proven role in prevention or in healthy eyes.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.69
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Disputed
Confidence
76%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L2 PubMedPrimary literature
0.60
L11 AI re-checkIndependent read
0.65
L3 MechanismPlausibility
0.75
L5 Clinical bodiesAuthoritative stance
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.695
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial
PMID: 23644932 2013 隨機對照試驗 n = 4,203
Finding: 主要分析中,葉黃素/玉米黃素相較安慰劑未達統計顯著的整體效益;但在飲食攝取量最低五分位的次族群有顯著保護作用
🟢 High quality Government Effect size: 整體 HR 0.90 (P=.12);最低飲食攝取五分位次族群 HR 0.74 (95% CI 0.59-0.94, P=.01)
View on PubMed
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3
PMID: 24310343 2014 Other n = 4,203
Finding: 在直接與 beta-carotene 比較時,葉黃素/玉米黃素顯著降低晚期 AMD 與新生血管型 AMD 的進展風險;雙眼大型 drusen 次族群效益最明顯
Government Effect size: 葉黃素/玉米黃素 vs 安慰劑 晚期 AMD HR 0.90 (95% CI 0.82-0.99, P=.04);vs beta-carotene HR 0.82 (95% CI 0.69-0.96, P=.02);新生血管型 AMD HR 0.78 (95% CI 0.64-0.94, P=.01)
View on PubMed
Long-term Outcomes of Adding Lutein/Zeaxanthin and omega-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28
PMID: 35653117 2022 Other n = 3,882
Finding: 10 年追蹤確認葉黃素/玉米黃素相較 beta-carotene 在降低晚期 AMD 進展上更有利,且不增加肺癌風險,支持以葉黃素/玉米黃素取代 beta-carotene
🟢 High quality Government Effect size: 晚期 AMD 進展 葉黃素/玉米黃素 vs beta-carotene HR 0.85 (95% CI 0.73-0.98, P=.02);beta-carotene 組肺癌 OR 1.82 (95% CI 1.06-3.12)
View on PubMed
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
PMID: 28756618 2017 Cochrane SR n = 6,891
Finding: 服用葉黃素/玉米黃素者進展至晚期 AMD 的風險與對照組相近或略為降低;證據確定性低,效益有限
🟢 High quality Effect size: 進展至晚期 AMD RR 0.94 (95% CI 0.87-1.01);證據確定性:低 (low-certainty GRADE)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
FDA has no questions; some uses may require a color additive listing source↗
L4b EU EFSA
Against
L4c UK NHS
Against
Prescribers should not initiate lutein and antioxidants for any new patient, and patients currently being prescribed these products should be reviewed and treatment stopped. source↗
L4d TW TFDA / 衛福部
Neutral
膠囊錠狀食品中每日食用量標示者,每人每日葉黃素食用量不得超過30毫克;未標示每日食用量者,每300公克中葉黃素含量不得超過9毫克。 source↗
L4e WHO
Not addressed
Based on the absence of toxicity in a wide range of studies, the Committee at its 86th meeting established a group ADI 'not specified' for lutein from Tagetes erecta, lutein esters from Tagetes erecta and zeaxanthin (synthetic). The decision was based on the absence of any observed toxicity of lutein or lutein esters in toxicological studies in animals, the absence of any adverse effects in hum… source↗
L5a NIH Office of Dietary Supplements
Supportive
L5b Mayo Clinic
Supportive
L5c Cleveland Clinic
Supportive
L5d Harvard Health
Supportive
L5e Specialty Society (condition-mapped)
Supportive
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-amd-INT-lutein-001 繁體中文版 →